Both responder and remitter patients experienced a statistically significant longer time to relapse with esketamine compared to the placebo
Shyam Patel, PharmD
Advertisement
Articles by Shyam Patel, PharmD
FDA approves lofexidine for opioid withdrawal symptoms.
Advertisement
Latest Updated Articles
What Pharmacists Need to Know About LofexidinePublished: October 1st 2018 | Updated:
New Drug Review: SpravatoPublished: June 13th 2019 | Updated:
Advertisement
Advertisement
Trending on Drug Topics
1
Eli Lilly, Walmart Announce Expansion of Direct-to Consumer Access for Tirzepatide
2
Pass-Through Rebate Law Uncovering New PBM Tactics, Entities | NCPA 2025
3
Community Pharmacies Need to Better Prioritize Whole-Person Health Care | NCPA 2025
4
FDA Approves Mirikizumab as Once Monthly Injection for Moderately to Severely Active Ulcerative Colitis
5
